September 2023 in “Journal of the American Academy of Dermatology” This study found that the incidence of major adverse cardiovascular events in patients with psoriasis, psoriatic arthritis, and axial spondyloarthritis who received Ixekizumab was low and stable over 3 to 5 years across 25 clinical trials.
April 2023 in “Research Square (Research Square)” This study found that lower GPX4 mRNA levels in polymorphonuclear neutrophils of systemic lupus erythematosus patients were negatively associated with disease activity and serological markers, suggesting a diagnostic value for GPX4 mRNA.
19 citations
,
March 2018 in “Expert Opinion on Drug Safety” In this narrative review, the researchers reported that the overall safety profile of drugs used for treating spondyloarthritis is generally good, with serious adverse events being rare, but emphasized the need for rheumatologists to tailor treatments and closely monitor patients for potential adverse events.
February 2024 in “Curēus” In this case report, secukinumab therapy for spondyloarthritis was associated with the development of alopecia areata in a 46-year-old woman, which improved after discontinuing the medication.
July 2016 in “Reumatología Clínica (English Edition)” This review discusses the wide range of physiologic skin changes during pregnancy and highlights less frequently recognized changes, based on literature from the past decade, without reporting new clinical results.